Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11197821 Formulations for treatment of dry eye disease

Patent 11197821 was granted and assigned to Aldeyra Therapeutics on December, 2021 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Aldeyra Therapeutics

Current Assignee

Aldeyra Therapeutics

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

111978210

Patent Inventor Names

Susan Macdonald0

Stephen Gitu Machatha0

Todd Brady0

David Clark0

Date of Patent

December 14, 2021

Patent Application Number

165827200

Date Filed

September 25, 2019

Patent Citations Received

‌

US Patent 12128013 Toxic aldehyde related diseases and treatment

‌

US Patent 11583529 Treatment of inflammatory disorders

‌

US Patent 11701331 Toxic aldehyde related diseases and treatment

‌

US Patent 11771664 Toxic aldehyde related diseases and treatment

‌

US Patent 11786518 Ophthalmic formulations and uses thereof

‌

US Patent 12006298 Polymorphic compounds and uses thereof

‌

US Patent 12064516 Pharmaceutical formulations and uses thereof

Patent Primary Examiner

‌

Tracy Vivlemore

Patent abstract

The present invention provides a reproxalap ophthalmic solution, and methods of using the same for treating dry eye disease.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11197821 Formulations for treatment of dry eye disease

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API